← Evidence map

TrialCardiovascular diabetology2025

Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial.

Hiroki Teragawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial. | Socratic